The key binary catalyst is the primary endpoint data readout in Q2 2027. The pilot MODERATO II data showed a net 8.1 mmHg reduction in 24-hour aSBP vs control at 6 months, providing a benchmark. Watch for any pre-announcements or analyst day commentary on the trial's blinded aggregate event rates or follow-up completion pace before the conference submission window.
Price Chart
Executive Summary
Orchestra BioMed announced that its BACKBEAT global pivotal trial of AVIM Therapy has exceeded full enrollment, with 330 patients randomized as of September 30, 2026, surpassing the target of 316. The company reiterated guidance for primary endpoint data submission for a late-breaking presentation at a major cardiovascular conference in Q2 2027. This is a clinical milestone de-risking event that removes enrollment uncertainty and keeps the pivotal trial on schedule.
Key Facts
- 330 patients randomized as of September 30, 2026, exceeding the target of 316
- Trial conducted at 81 sites across 13 countries with Medtronic (NYSE: MDT)
- Primary endpoint data to be submitted for late-breaking presentation consideration at a major cardiovascular conference in Q2 2027
- Protocol specifies 284 evaluable randomized subjects for primary endpoint analysis
- Trial is a global, multi-center, prospective, randomized, double-blind pivotal study
- Primary efficacy endpoint: between-group difference in change in 24-hour ambulatory systolic blood pressure at 3-month follow-up
- Primary safety endpoint: freedom from unanticipated serious adverse device events at 3-month follow-up
- Study designed with >90% statistical power to detect at least 5 mmHg between-group difference in aSBP
- AVIM Therapy has FDA Breakthrough Device Designations for uncontrolled hypertension in patients with increased cardiovascular risk
- Medtronic plans to submit marketing applications to FDA and other global regulators promptly assuming positive results
Financial Impact
No financial figures reported. Clinical milestone removes enrollment risk for a pivotal trial targeting a multi-billion-dollar annual market opportunity (uncontrolled hypertension in pacemaker-indicated patients).
Risk Factors
- Primary endpoint results may fail to show statistically significant blood pressure reduction vs control
- Safety events could emerge at the 3-month follow-up, impacting the safety endpoint
- Regulatory approval and commercialization depend on Medtronic's subsequent marketing applications, which are not guaranteed
- Competing hypertension devices or therapies could emerge before or after data readout
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-112586 |
| Document: tm2626728d1_ex99-1.htm | 0001104659-26-112586 |
| Document: 0001104659-26-112586-index-headers.html | 0001104659-26-112586 |
| Document: 0001104659-26-112586-index.html | 0001104659-26-112586 |
| Document: 0001104659-26-112586.txt | 0001104659-26-112586 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 26d ago | 144 | $6.35 $5.73 | ▼ −9.76% | ▼ −11.06% | $5.55 (−12.60%) |
Oct 1, 2026 26d ago | 8-K | $6.35 $5.73 | ▼ −9.76% | ▼ −11.06% | $5.55 (−12.60%) |
Sep 22, 2026 4w ago | Institutional Cluster | $6.22 $6.08 | ▼ −2.25% | ▼ −1.06% | $5.55 (−10.77%) |
Sep 8, 2026 7w ago | Insider Cluster | $5.43 $6.04 | ▲ +11.23% | ▲ +12.35% | $5.55 (+2.21%) |
Sep 1, 2026 8w ago | 144 | $4.90 $5.45 | ▼ −11.22% | ▼ −11.14% | $5.55 (−13.27%) |
Jul 1, 2026 16w ago | 144 | $4.30 $3.96 | ▼ −7.91% | ▼ −8.17% | $5.55 (+29.07%) |
Jun 2, 2026 20w ago | Insider Cluster | $3.86 $4.02 | ▲ +4.15% | ▲ +7.96% | $5.55 (+43.78%) |
May 19, 2026 23w ago | Insider Cluster | $4.00 $4.06 | ▲ +1.50% | ▼ −0.75% | $5.55 (+38.75%) |
Apr 29, 2026 25w ago | DEFA14A | $3.99 $3.93 | ▼ −1.50% | ▼ −3.23% | $5.55 (+39.10%) |
Apr 23, 2026 26w ago | Press Release | $4.15 $3.80 | ▼ −8.43% | ▼ −9.91% | $5.55 (+33.73%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers